These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

343 related articles for article (PubMed ID: 22717453)

  • 1. Work disability in inflammatory bowel disease patients 10 years after disease onset: results from the IBSEN Study.
    Høivik ML; Moum B; Solberg IC; Henriksen M; Cvancarova M; Bernklev T;
    Gut; 2013 Mar; 62(3):368-75. PubMed ID: 22717453
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Change of diagnosis during the first five years after onset of inflammatory bowel disease: results of a prospective follow-up study (the IBSEN Study).
    Henriksen M; Jahnsen J; Lygren I; Sauar J; Schulz T; Stray N; Vatn MH; Moum B;
    Scand J Gastroenterol; 2006 Sep; 41(9):1037-43. PubMed ID: 16938716
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical course during the first 10 years of ulcerative colitis: results from a population-based inception cohort (IBSEN Study).
    Solberg IC; Lygren I; Jahnsen J; Aadland E; Høie O; Cvancarova M; Bernklev T; Henriksen M; Sauar J; Vatn MH; Moum B;
    Scand J Gastroenterol; 2009; 44(4):431-40. PubMed ID: 19101844
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Crohn's disease and ulcerative colitis. Occurrence, course and prognosis during the first year of disease in a European population-based inception cohort.
    Burisch J
    Dan Med J; 2014 Jan; 61(1):B4778. PubMed ID: 24393595
    [TBL] [Abstract][Full Text] [Related]  

  • 5. C-reactive protein: a predictive factor and marker of inflammation in inflammatory bowel disease. Results from a prospective population-based study.
    Henriksen M; Jahnsen J; Lygren I; Stray N; Sauar J; Vatn MH; Moum B;
    Gut; 2008 Nov; 57(11):1518-23. PubMed ID: 18566104
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Work disability and productivity loss in patients with inflammatory bowel diseases in Hungary in the era of biologics.
    Mandel MD; Bálint A; Lovász BD; Gulácsi L; Strbák B; Golovics PA; Farkas K; Kürti Z; Szilágyi BK; Mohás A; Molnár T; Lakatos PL
    Eur J Health Econ; 2014 May; 15 Suppl 1():S121-8. PubMed ID: 24832845
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of phenotype at diagnosis and of other potential prognostic factors on the course of inflammatory bowel disease.
    Romberg-Camps MJ; Dagnelie PC; Kester AD; Hesselink-van de Kruijs MA; Cilissen M; Engels LG; Van Deursen C; Hameeteman WH; Wolters FL; Russel MG; Stockbrügger RW
    Am J Gastroenterol; 2009 Feb; 104(2):371-83. PubMed ID: 19174787
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk factors of work disability in patients with inflammatory bowel disease--a Dutch nationwide web-based survey: work disability in inflammatory bowel disease.
    van der Valk ME; Mangen MJ; Leenders M; Dijkstra G; van Bodegraven AA; Fidder HH; de Jong DJ; Pierik M; van der Woude CJ; Romberg-Camps MJ; Clemens CH; Jansen JM; Mahmmod N; van de Meeberg PC; van der Meulen-de Jong AE; Ponsioen CY; Bolwerk CJ; Vermeijden JR; Siersema PD; van Oijen MG; Oldenburg B; ;
    J Crohns Colitis; 2014 Jul; 8(7):590-7. PubMed ID: 24351733
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical course in Crohn's disease: results of a five-year population-based follow-up study (the IBSEN study).
    Henriksen M; Jahnsen J; Lygren I; Aadland E; Schulz T; Vatn MH; Moum B;
    Scand J Gastroenterol; 2007 May; 42(5):602-10. PubMed ID: 17454881
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Complementary and alternative medicine in patients with inflammatory bowel disease: the results of a population-based inception cohort study (IBSEN).
    Opheim R; Hoivik ML; Solberg IC; Moum B;
    J Crohns Colitis; 2012 Apr; 6(3):345-53. PubMed ID: 22405172
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Natural history of elderly-onset inflammatory bowel disease: a population-based cohort study.
    Charpentier C; Salleron J; Savoye G; Fumery M; Merle V; Laberenne JE; Vasseur F; Dupas JL; Cortot A; Dauchet L; Peyrin-Biroulet L; Lerebours E; Colombel JF; Gower-Rousseau C
    Gut; 2014 Mar; 63(3):423-32. PubMed ID: 23408350
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Decreasing risk of colorectal cancer in patients with inflammatory bowel disease over 30 years.
    Jess T; Simonsen J; Jørgensen KT; Pedersen BV; Nielsen NM; Frisch M
    Gastroenterology; 2012 Aug; 143(2):375-81.e1; quiz e13-4. PubMed ID: 22522090
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early azathioprine/biological therapy is associated with decreased risk for first surgery and delays time to surgery but not reoperation in both smokers and nonsmokers with Crohn's disease, while smoking decreases the risk of colectomy in ulcerative colitis.
    Szamosi T; Banai J; Lakatos L; Czegledi Z; David G; Zsigmond F; Pandur T; Erdelyi Z; Gemela O; Papp M; Papp J; Lakatos PL
    Eur J Gastroenterol Hepatol; 2010 Jul; 22(7):872-9. PubMed ID: 19648821
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Disease outcome of inflammatory bowel disease patients: general outline of a Europe-wide population-based 10-year clinical follow-up study.
    Wolters FL; Russel MG; Sijbrandij J; Schouten LJ; Odes S; Riis L; Munkholm P; Langholz E; Bodini P; O'Morain C; Katsanos K; Tsianos E; Vermeire S; Van Zeijl G; Limonard C; Hoie O; Vatn M; Moum B; Stockbrügger RW;
    Scand J Gastroenterol Suppl; 2006; (243):46-54. PubMed ID: 16782622
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationship between clinical parameters and the colitis-colorectal cancer interval in a cohort of patients with colorectal cancer in inflammatory bowel disease.
    Brackmann S; Andersen SN; Aamodt G; Langmark F; Clausen OP; Aadland E; Fausa O; Rydning A; Vatn MH
    Scand J Gastroenterol; 2009; 44(1):46-55. PubMed ID: 18609187
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differences in phenotype and disease course in adult and paediatric inflammatory bowel disease--a population-based study.
    Jakobsen C; Bartek J; Wewer V; Vind I; Munkholm P; Groen R; Paerregaard A
    Aliment Pharmacol Ther; 2011 Nov; 34(10):1217-24. PubMed ID: 21981762
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk matrix model for prediction of colectomy in a population-based study of ulcerative colitis patients (the IBSEN study).
    Solberg IC; Høivik ML; Cvancarova M; Moum B;
    Scand J Gastroenterol; 2015; 50(12):1456-62. PubMed ID: 26139389
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort.
    Frøslie KF; Jahnsen J; Moum BA; Vatn MH;
    Gastroenterology; 2007 Aug; 133(2):412-22. PubMed ID: 17681162
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of complementary and alternative medicine in patients with inflammatory bowel disease: results of a cross-sectional study in Norway.
    Opheim R; Bernklev T; Fagermoen MS; Cvancarova M; Moum B
    Scand J Gastroenterol; 2012 Dec; 47(12):1436-47. PubMed ID: 23003678
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Infliximab and other immunomodulating drugs in patients with inflammatory bowel disease and the risk of serious bacterial infections.
    Schneeweiss S; Korzenik J; Solomon DH; Canning C; Lee J; Bressler B
    Aliment Pharmacol Ther; 2009 Aug; 30(3):253-64. PubMed ID: 19438424
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.